|Meta-analysis of first-line therapies in advanced non–small-cell lung cancer harboring EGFR-activating mutations|
B Haaland, P San Tan, G de Castro Jr, G Lopes
Journal of Thoracic Oncology 9 (6), 805, 2014
|Clinician-targeted interventions to influence antibiotic prescribing behaviour for acute respiratory infections in primary care: an overview of systematic reviews.|
CBDM SK Tonkin-Crine, PS Tan, O van Hecke, K Wang, NW Roberts, A McCullough ...
The Cochrane database of systematic reviews 9, CD012252, 2017
|The challenge of antimicrobial resistance: what economics can contribute|
LSJ Roope, RD Smith, KB Pouwels, J Buchanan, L Abel, P Eibich, ...
Science 364 (6435), 2019
|Cost-effectiveness of Osimertinib in the first-line treatment of patients with EGFR-Mutated advanced non–Small cell lung Cancer|
PN Aguiar, B Haaland, W Park, P San Tan, A del Giglio, G de Lima Lopes
JAMA oncology 4 (8), 1080-1084, 2018
|Ten-year survival in women with primary stage IV breast cancer|
LG Eng, S Dawood, V Sopik, B Haaland, P San Tan, N Bhoo-Pathy, ...
Breast cancer research and treatment 160 (1), 145-152, 2016
|Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer–A systematic review and network meta-analysis of 3024 …|
P San Tan, P Aguiar Jr, B Haaland, G Lopes
Lung Cancer 115, 84-88, 2018
|Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison|
PS Tan, B Haaland, AJ Montero, CE Kyriakopoulos, G Lopes
Clinical Medicine Insights: Oncology 8, CMO. S13671, 2014
|A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer|
P San Tan, B Haaland, AJ Montero, G Lopes
Breast cancer research and treatment 138 (3), 961-965, 2013
|The clinical utility of point-of-care tests for influenza in ambulatory care: A systematic review and meta-analysis|
JJ Lee, JY Verbakel, CR Goyder, T Ananthakumar, PS Tan, PJ Turner, ...
Clinical Infectious Diseases 69 (1), 24-33, 2019
|Overview of systematic reviews assessing the evidence for shorter versus longer duration antibiotic treatment for bacterial infections in secondary care|
IJ Onakpoya, AS Walker, PS Tan, EA Spencer, OA Gbinigie, J Cook, ...
PloS one 13 (3), e0194858, 2018
|Childhood drowning in Malaysia|
AS Hss, PS Tan, L Hashim
International journal of injury control and safety promotion 21 (1), 75-80, 2014
|Impact of point-of-care C reactive protein in ambulatory care: a systematic review and meta-analysis|
JY Verbakel, JJ Lee, C Goyder, P San Tan, T Ananthakumar, PJ Turner, ...
BMJ open 9 (1), e025036, 2019
|Meta‐analysis of first‐line therapies with maintenance regimens for advanced non‐small‐cell lung cancer (NSCLC) in molecularly and clinically selected populations|
PS Tan, M Bilger, G de Lima Lopes, S Acharyya, B Haaland
Cancer medicine 6 (8), 1847-1860, 2017
|Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a …|
P San Tan, P Aguiar, B Haaland, G Lopes
Prostate cancer and prostatic diseases 21 (4), 516-523, 2018
|Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after …|
P San Tan, G Lopes, S Acharyya, M Bilger, B Haaland
European Journal of Cancer 51 (16), 2330-2344, 2015
|A systematic review and meta-analyses of the association between anti-hypertensive classes and the risk of falls among older adults|
HT Ang, KK Lim, YH Kwan, P San Tan, KZ Yap, Z Banu, CS Tan, W Fong, ...
Drugs & aging 35 (7), 625-635, 2018
|Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer|
PN Aguiar Jr, P San Tan, S Simko, CMN Barreto, B de Souza Gutierres, ...
Einstein 17 (2), 2019
|Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people|
J Hippisley-Cox, D Young, C Coupland, KM Channon, P San Tan, ...
Heart 106 (19), 1503-1511, 2020
|Anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer: A meta-analysis.|
PS Tan, B Haaland, AJ Montero, G Lopes
JOURNAL OF CLINICAL ONCOLOGY 31 (15), 2013
|Indirect Comparison between Immune-Checkpoint Inhibitors for 2nd Line Non-Small Cell Lung Cancer-a Network Meta-Analysis|
P Tan, P Aguiar Jr, B Haaland, G Lopes
JOURNAL OF THORACIC ONCOLOGY 12 (11), S2149-S2149, 2017